Carmustin en es it fr

Carmustin Brand names, Carmustin Analogs

Carmustin Brand Names Mixture

  • No information avaliable

Carmustin Chemical_Formula


Carmustin RX_link

Carmustin fda sheet

Carmustin msds (material safety sheet)

Carmustin MSDS

Carmustin Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Carmustin Molecular Weight

214.049 g/mol

Carmustin Melting Point

31 oC

Carmustin H2O Solubility

< 0.1 g/100 mL at 18 °C

Carmustin State


Carmustin LogP


Carmustin Dosage Forms

Powder for solution; Wafer

Carmustin Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Carmustin Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Carmustin Absorption

5 to 28% bioavailability

Carmustin side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Carmustin Patient Information

No information avaliable

Carmustin Organisms Affected

Humans and other mammals